263 related articles for article (PubMed ID: 24918318)
1. Skin reactions during anti-TNFα therapy for pediatric inflammatory bowel disease: a 2-year prospective study.
Mälkönen T; Wikström A; Heiskanen K; Merras-Salmio L; Mustonen H; Sipponen T; Kolho KL
Inflamm Bowel Dis; 2014 Aug; 20(8):1309-15. PubMed ID: 24918318
[TBL] [Abstract][Full Text] [Related]
2. The long-term outcome of anti-tumor necrosis factor-α therapy related to fecal calprotectin values during induction therapy in pediatric inflammatory bowel disease.
Kolho KL; Sipponen T
Scand J Gastroenterol; 2014 Apr; 49(4):434-41. PubMed ID: 24597837
[TBL] [Abstract][Full Text] [Related]
3. Infliximab-induced skin manifestations in patients with inflammatory bowel disease.
Hellström AE; Färkkilä M; Kolho KL
Scand J Gastroenterol; 2016; 51(5):563-71. PubMed ID: 26728295
[TBL] [Abstract][Full Text] [Related]
4. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases.
Guerra I; Algaba A; Pérez-Calle JL; Chaparro M; Marín-Jiménez I; García-Castellanos R; González-Lama Y; López-Sanromán A; Manceñido N; Martínez-Montiel P; Quintanilla E; Taxonera C; Villafruela M; Romero-Maté A; López-Serrano P; Gisbert JP; Bermejo F
J Crohns Colitis; 2012 Jun; 6(5):518-23. PubMed ID: 22398059
[TBL] [Abstract][Full Text] [Related]
5. A one-hour infusion of infliximab during maintenance therapy is safe and well tolerated: a prospective cohort study.
Lee TW; Singh R; Fedorak RN
Aliment Pharmacol Ther; 2011 Jul; 34(2):181-7. PubMed ID: 21615434
[TBL] [Abstract][Full Text] [Related]
6. Psoriasis induced by infliximab in a patient suffering from Crohn's disease.
Manni E; Barachini P
Int J Immunopathol Pharmacol; 2009; 22(3):841-4. PubMed ID: 19822070
[TBL] [Abstract][Full Text] [Related]
7. Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort.
Bálint A; Rutka M; Végh Z; Kürti Z; Gecse KB; Banai J; Bene L; Gasztonyi B; Kristóf T; Lakatos L; Miheller P; Palatka K; Patai Á; Salamon Á; Szamosi T; Szepes Z; Tóth GT; Vincze Á; Bor R; Milassin Á; Fábián A; Nagy F; Kolar M; Bortlik M; Duricova D; Hruba V; Lukas M; Mitrova K; Malickova K; Lukas M; Lakatos PL; Molnár T; Farkas K
Expert Opin Drug Saf; 2017 Aug; 16(8):885-890. PubMed ID: 28504555
[TBL] [Abstract][Full Text] [Related]
8. Infliximab therapy in children and adolescents with inflammatory bowel disease.
Veres G; Baldassano RN; Mamula P
Drugs; 2007; 67(12):1703-23. PubMed ID: 17683171
[TBL] [Abstract][Full Text] [Related]
9. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
10. Infliximab administered with shortened infusion times in a specialized IBD infusion unit: a prospective cohort study.
Van Assche G; Vermeire S; Noman M; Amant C; Weyts E; Vleminckx A; Vermeyen MJ; Rutgeerts P
J Crohns Colitis; 2010 Sep; 4(3):329-33. PubMed ID: 21122522
[TBL] [Abstract][Full Text] [Related]
11. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease.
Clare DF; Alexander FC; Mike S; Dan G; Allan F; Lisa W; Peter HJ
Eur J Gastroenterol Hepatol; 2009 Jan; 21(1):71-5. PubMed ID: 19060632
[TBL] [Abstract][Full Text] [Related]
12. IgE antibodies and skin tests in immediate hypersensitivity reactions to infliximab in inflammatory bowel disease: impact on infliximab retreatment.
Fréling E; Peyrin-Biroulet L; Poreaux C; Morali A; Waton J; Schmutz JL; Guéant JL; Barbaud A
Eur J Gastroenterol Hepatol; 2015 Oct; 27(10):1200-8. PubMed ID: 26181108
[TBL] [Abstract][Full Text] [Related]
13. Are accelerated infliximab infusions safe in patients with inflammatory bowel disease?
Bhat S; Sharma D; Doherty P; Tham TC; Caddy GR
Inflamm Bowel Dis; 2010 Nov; 16(11):1922-5. PubMed ID: 20848465
[TBL] [Abstract][Full Text] [Related]
14. Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents.
Eickstaedt JB; Killpack L; Tung J; Davis D; Hand JL; Tollefson MM
Pediatr Dermatol; 2017 May; 34(3):253-260. PubMed ID: 28211161
[TBL] [Abstract][Full Text] [Related]
15. Five cases of anti-tumor necrosis factor alpha-induced psoriasis presenting with severe scalp involvement in children.
Perman MJ; Lovell DJ; Denson LA; Farrell MK; Lucky AW
Pediatr Dermatol; 2012; 29(4):454-9. PubMed ID: 21995665
[TBL] [Abstract][Full Text] [Related]
16. Does infliximab short infusion have a beneficial impact on the quality of life in patients with inflammatory bowel diseases? A single centre prospective evaluation.
Principi M; Losurdo G; La Fortezza RF; Lopolito P; Lovero R; Grillo S; Bringiotti R; Ierardi E; Di Leo A
J Gastrointestin Liver Dis; 2015 Jun; 24(2):165-70. PubMed ID: 26114175
[TBL] [Abstract][Full Text] [Related]
17. Prevention of acute adverse events related to infliximab infusions in pediatric patients.
Lahdenne P; Wikström AM; Aalto K; Kolho KL
Arthritis Care Res (Hoboken); 2010 Jun; 62(6):785-90. PubMed ID: 20535789
[TBL] [Abstract][Full Text] [Related]
18. Use of infliximab in pediatric patients with inflammatory bowel disease.
Serrano MS; Schmidt-Sommerfeld E; Kilbaugh TJ; Brown RF; Udall JN; Mannick EE
Ann Pharmacother; 2001; 35(7-8):823-8. PubMed ID: 11485127
[TBL] [Abstract][Full Text] [Related]
19. Psoriasiform and pustular eruption induced by infliximab.
Takahashi H; Hashimoto Y; Ishida-Yamamoto A; Ashida T; Kohgo Y; Iizuka H
J Dermatol; 2007 Jul; 34(7):468-72. PubMed ID: 17584325
[TBL] [Abstract][Full Text] [Related]
20. Outcome after discontinuation of TNFα-blocking therapy in patients with inflammatory bowel disease in deep remission.
Molander P; Färkkilä M; Salminen K; Kemppainen H; Blomster T; Koskela R; Jussila A; Rautiainen H; Nissinen M; Haapamäki J; Arkkila P; Nieminen U; Kuisma J; Punkkinen J; Kolho KL; Mustonen H; Sipponen T
Inflamm Bowel Dis; 2014 Jun; 20(6):1021-8. PubMed ID: 24798636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]